Shares of Moderna slid 6.76% to $148.59 at 15:34 EST on Tuesday, following last session’s downward trend. NASDAQ Composite is sliding 1.28% to $13,360.07, following last session’s downward trend, This seems, as yet, an all-around rough trend trading session today.
Moderna’s last close was $159.37, 27.37% under its 52-week high of $189.26.
Moderna’s sales growth is 1888% for the current quarter and 17655% for the next. The company’s growth estimates for the current quarter and the next is 5.4% and 577.1%, respectively.
Year-on-year quarterly revenue growth grew by 826.4%, now sitting on 246.7M for the twelve trailing months.
Moderna’s last day, last week, and last month’s average volatility was 9.64%, 4.17%, and 4.02%, respectively.
Moderna’s last day, last week, and last month’s high and low average amplitude percentage was 7.42%, 5.38%, and 6.82%, respectively.
Moderna’s Stock Yearly Top and Bottom Value
Moderna’s stock is valued at $148.59 at 15:34 EST, way under its 52-week high of $189.26 and way higher than its 52-week low of $19.31.
Moderna’s Moving Average
Moderna’s worth is below its 50-day moving average of $149.83 and way above its 200-day moving average of $103.71.
Previous days news about Moderna
Moderna says FDA gave positive feedback on dose-per-vial shift. According to Bloomberg Quint on Monday, 22 February, "By making each vial more efficient, Slaoui said, Moderna will be able to circumvent some of the headwinds faced in the last stage of the production process, known as fill-finish, where the vaccine’s substance is placed in vials, packaged and distributed.", "Discussion between Moderna and the U.S. government about increasing the number of doses per vial began with the Trump administration’s Operation Warp Speed program, according to its former Chief Scientific Adviser Moncef Slaoui."